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ABSTRACT  
Background:  Many  species  of  hallucinogenic  mushrooms  have  been  found  in  the  genus 
Psilocybe.  The  main  psychoactive  chemicals  of  Psilocybe  mushrooms  are  psilocin  and  its 
phosphoryloxy  derivative,  psilocybin.  In  addition  to  its  psychedelic  effects,  psilocybin  is  an 
effective agent to lift the mood of depressed patients with terminal cancers.  
 
Objective: To study the dispositional kinetics of 
14C-psilocin in pregnant rats after intravenous 
injection, to calculate tissue dose surrogates i.e., tissue 
14C concentration and area under the 
concentration-time  curve  using  the  experimental  data,  to  quantify  trans-placental  passage  of 
psilocin and/or its metabolites, and to identify new psilocin metabolite(s) in rat urine. 
 
Methods: A group of 15 pregnant Wistar rats weighing between 0.30-0.36 kg was used in the 
study. Each rat was given a single dose of 7.5 mg/kg 
14C-psilocin
 i.v. Three rats were randomly 
selected and sacrificed at 0.5, 1.0, 2.0, 4.0, and 8.0 hr post-dosing. The maternal and fetal tissues 
were quickly removed and the radioactivity in these tissues determined by liquid scintillation 
counting. 
In a separate study, urine samples were collected from 6 male Wistar rats after administering 
15  mg/kg  of  unlabeled  psilocin  i.p.  The  urine  samples  were  collected  and  extracted  by 
chloroform-methanol (9:1 v/v) and analyzed using a gas chromatograph/mass spectrometer.  
 
Results: 
14C-Psilocin  crossed  the  placental  barrier  of  pregnant  rats  readily  after  i.v. 
administration; maternal tissue 
14C concentrations were found to be much higher than those in 
fetal tissues. The areas under the curve for maternal tissues also were much higher than the fetal 
tissues. In general, maternal tissues could be divided into the fast eliminating organ group, which Functional Foods in Health and Disease 2014; 4(6):232-244                                                           Page 233 of 244 
included the brain (elimination half-life <13 hr) and the slow eliminating organ group, which 
included all fetal tissues (elimination half-life >13 hr). A new psilocin metabolite tentatively 
identified as dihydroxyindoleacetic acid was found in the urine.  
 
Conclusion:  Our  study  showed  that  psilocin  readily  crossed  the  placental  and  blood-brain 
barriers of pregnant rats. Because psilocin was eliminated slowly from the fetal tissues of rats, 
human consumption of magic mushrooms should be avoided during pregnancy.   
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BACKGROUND: 
Recreational use of indigenous Psilocybe mushrooms has become very popular in many parts of 
the  world.  Psilocin  and  its  phosphoryloxy  derivative,  psilocybin,  are  the  major  psychoactive 
compounds  of  the  hallucinogenic  mushrooms  [1].  Indeed,  the  psychedelic  effect  of 
psilocybin/psilocin is mediated mainly via the serotonin 5-HT2A receptors [2] and may vary with 
the mushroom species, location of growth, and harvesting seasons.  
The  pharmacokinetics  and  tissue  distribution  of  psilocybin/psilocin  have  been  studied 
extensively in rodents [3, 4] and humans [5]. 
14C-Psilocin is absorbed rapidly by male rats after 
receiving a single dose orally [6]. After absorption, psilocin is distributed by the blood to the 
whole body and 
14C level in tissues is found to decrease in the order of kidney > liver > brain > 
blood. About 60% of the orally administered 
14C-psilocin was excreted in the urine and 21% in 
the feces within 1 day post-dosing. Significant amounts of psilocin also have been detected in the 
kidney, liver and brain of mice after receiving a single oral dose of psilocybin [3].   
Psilocybin  is  rapidly  hydrolyzed  to  psilocin  by  alkaline  phosphatase  or  esterases  in  the 
gastrointestinal  tract  and/or  liver  [3,  6-8].  The  fact  that  the  phosphoric  acid  ester  group  of 
psilocybin is rapidly hydrolyzed indicates psilocin is the actual bioactive component of magic 
mushrooms and psilocybin merely acts as a pro-drug (Figure 1). Kalberer et al. [6] have reported 
that less than 4% of the psilocin administered to rats is metabolized to 4-hydroxy-3-indoleacetic 
acid (4-HIAA) and no glucuronide metabolites have been found in the rat study. In contrast, 
psilocin O-glucuronide is found in the serum of human volunteers dosed with psilocin orally [9]. 
Indeed,  more  than  80%  of  the  psilocin  administered  to  humans  is  metabolized  to  psilocin 
glucuronides.  In  vitro  psilocin  glucuronidation  also  has  been  studied  using  19  recombinant 
human UDP glucuronosyltransferases of the subfamilies 1A, 2A and 2B [10]. Holzmann et al. 
[1]  have  shown  that  psilocin  may  undergo  enzymatic  oxidation  in  humans  to  form  4-
hydroxytryptophole  (4-HT)  and  4-hydroxyindole-3-acetaldehyde,  which  may  be  further 
metabolized to 4-HIAA. 
A recent study has shown that psilocybin is able to lift the moods of patients with advanced-
stage cancer at a moderate dose of 0.2 mg/kg [11]. The mechanism of anti-depression effect is 
not fully understood, but psilocybin is able to lower the elevated medial prefrontal cortex activity 
in patients suffering from depression. The anti-depression effect of psilocybin also is explainable 
by an increased emotional insight of the depressed patients after lowering their psychological Functional Foods in Health and Disease 2014; 4(6):232-244                                                           Page 234 of 244 
defense  [12].  In  addition  to  its  anti-depression  effect,  psilocybin  has  been  used  to  induce 
schizophrenic psychosis in healthy volunteers [13, 14].  
 
 
Figure 1. Psilocybin and psilocin biotransformation  
 
Despite the widespread use of Psilocybe mushrooms [15-18], very little is known of the 
dispositional kinetics and the tissue dose [19] of psilocin in pregnant animals. Andersen [19] has 
reported  that  tissue  concentrations  and  areas  under  the  curve  (AUC0-last)  of  a  drug  from 
pharmacokinetic  studies  can  be  used  as  quantitative  measures  of  tissue  dose  which  may  be 
unattainable  by  direct  experimentation.  The  objectives  of  this  study  were  to  study  the 
dispositional kinetics of 
14C-psilocin in pregnant rats after intravenous injection, to calculate 
tissue dose surrogates i.e., tissue 
14C concentration and AUC0-last using the experimental data, to 
quantify trans-placental passage of psilocin and/or its metabolites, and to present preliminary 
findings on the identity of a new psilocin metabolite in rat urine. In view of the potential use of 
magic mushrooms as an anti-depressant in humans, it is important to study the placental transfer 
of psilocin in pregnant animals. As tissue dose is a measure of the intensity of tissue exposure to 
psilocin [19], the present study will provide the information needed to evaluate the effectiveness 
and safety of psilocin in humans. 
 
MATERIALS AND METHODS: 
Chemicals:  Unlabeled  psilocin  was  a  product  of  Sandoz  Pharmaceutical  Ltd.  (Basel, 
Switzerland). Chemical purity of unlabeled psilocin was >99%. 
14C-Labeled psilocin (specific 
activity 0.0878 Ci/mg) was synthesized chemically in our laboratory according to Poon et al. 
[20]. Radiochemical purity of 
14C-psilocin was determined to be >98%. A license was obtained 
from Health Canada for the synthesis, storage and handling of the Schedule 1 drug. A solution of 
14C-labeled psilocin was prepared by mixing 
14C-labeled psilocin and unlabeled psilocin together Functional Foods in Health and Disease 2014; 4(6):232-244                                                           Page 235 of 244 
in distilled water such that the administration of 0.5 ml of the solution provided the desired dose 
of the test chemical. 
 
Animals: Fifteen pregnant Wistar rats weighing between 300-365 g (days 19-20 of gestation) 
and 6 male Wistar rats weighing between 250-300 g were purchased from Charles River Canada 
Inc. (St., Constant, Quebec). They were acclimatized in the Animal Care Facility of Simon Fraser 
University for 1 week before use. Commercial laboratory rat chow and water were provided ad 
libitum. The procedure associated with animal care and experimentation was conducted with the 
approval of the Animal Care Committee at Simon Fraser University.  
 
Animal  treatment:  The  tissue  distribution  study  was  initiated by  injecting 
14C-psilocin  (7.5 
mg/kg)
 i.v. to each of the 15 pregnant rats. Three rats were randomly selected from the group and 
sacrificed at specific time points post-dosing (0.5, 1.0, 2.0, 4.0, and 8.0 hr). Maternal blood and 
tissue  specimens  (e.g.,  liver,  kidney,  lung,  heart,  spleen,  brain,  and  muscle)  were  removed 
immediately from the rats. The fetuses were delivered via hysterectomy, and fetal blood, liver, 
lung, kidney, and heart samples were removed. All maternal and fetal tissue samples were stored 
at -10 
oC until analysis. 
Urine  samples  were  collected  from  6  male  Wistar  rats  after  receiving  a  single  dose  of 
unlabeled psilocin (15 mg/kg) i.p. The rats were kept in separate metabolic cages and the urine 
was  collected  daily  for  two  days.  The  urine  samples  were  pooled  and  stored  at  -10 
oC  for 
subsequent analysis. Control urine was collected from the rat prior to psilocin administration. 
 
Determination of radioactivity in tissues and biologic fluids: Blood samples were digested at 
50 
oC for 30 min in separate liquid scintillation vials containing 1 ml Protosol:ethanol (1:1 v/v). 
The vial was cooled, decolorized with 30 % hydrogen peroxide (0.5 ml) and neutralized by 0.5 N 
HCl (0.5 ml). After the addition of Biofluor (14 ml), the radioactivity in the vial was determined 
by a Beckman LS-8000 Liquid Scintillation Counter. 
14C concentration in blood was expressed 
as µg psilocin equivalents/ml blood. 
Tissue samples (0.5 -1.0 g) were weighed accurately on a piece of filter paper. The tissue 
was oxidized in a Tri-Carb B306 Sample Oxidizer (Packard Co., Downers Grove, Ill.).  The 
14CO2 evolved from burning the tissue was trapped in 6 ml of Carbo-Sorb in a liquid scintillation 
vial. After the addition of Permafluor (14 ml), the vial was counted by a LSC. 
14C concentration 
in tissue was expressed as µg psilocin equivalents/g tissue wet weight.  
 
Data analysis: Tissue/blood 
14C concentration data were plotted semi-logarithmically against the 
time of sample collection. The resulting concentration-time curves were analyzed using the non-
compartmental approach of WinNonlin
® pharmacokinetic package (V1.0, SCI software, Cary, 
North Carolina) to determine the t1/2β and AUC0-last (from 0 hour to the last time point) for each 
rat.  AUC0-last was calculated by the trapezoidal method. The mean + SD values of t1/2β and 
AUC0-last were calculated from three rats. 
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Isolation and characterization of urinary metabolites: The urine sample was thawed, rendered 
basic with NaHCO3, and extracted 3 times with diethyl ether to remove the unchanged psilocin. 
The remaining aqueous layer was acidified to pH 3 by HCl and extracted 3 times by chloroform-
methanol (9:1 v/v).  The chloroform-methanol extracts were combined and dried under a gentle 
stream of nitrogen. The residues were re-dissolved in methanol and transferred to a 1000 m 
thickness silica gel GF preparative TLC plate (20 X 20 cm Uniplate; Analtech Inc., Newark, DE) 
which was double-developed in CHCl3:CH3OH (9:1 v/v) to obtained good band separation. The 
psilocin metabolites were located by placing the plate under the UV light. The silica in the area 
containing the unknown metabolite was scrapped off from the plate and extracted 3 times with 
chloroform:methanol (1:1 v/v). The extracts were combined and dried under a stream of nitrogen. 
The  residues  were  analyzed  by  direct  probe  mass  spectrometry  operated  under  the  electron 
impact mode and at an ionization potential of 70 eV. The ion source was set at 200 
oC. Mass 
spectral service was provided by the Department of Chemistry, Simon Fraser University. 
 
RESULTS: 
Figure 2 shows the mean 
14C (psilocin plus metabolites) concentrations versus time curves in the 
maternal and fetal blood of the pregnant rats. Maximal 
14C concentrations were observed in the 
maternal and fetal blood at 0.5 hr (the first time point of sampling) after injecting 
14C-psilocin i.v. 
to  the  rats.  Both 
14C  concentration-time  profiles  showed  a  rapid,  biphasic  decline  of 
14C 
concentration with time. The maternal and fetal blood profiles appeared parallel to each other 
with maternal blood 
14C concentration 2.0-2.5 fold higher than fetal blood. The mean AUC0-last of 
the blood concentration-time curves, which represented psilocin doses in the maternal and fetal 
blood,  were  28.4  +  3.7  and  12.7  +  4.1  µg  psilocin  equivalents·hr/ml,  respectively.  The 
elimination half-life (t1/2β) of 
14C in the maternal and fetal blood curves was 19.8 + 2.6 and 14.9 
+ 4.7 hr, respectively. 
 
Figure 2. Mean 
14C concentration versus time curves for maternal and fetal blood in pregnant 
rats after receiving an i.v. injection of 7.5 mg/kg
 14C-psilocin. Error bars represent the standard 
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Figures 3, 4, 5 and 6, respectively show the time course of 
14C concentrations in the liver, 
lung, heart, and kidney of the pregnant rats. As with the blood concentration-time curve (Figure. 
2), 
14C levels in the maternal organs were much higher than the fetal tissues. 
   
 
 
Figure 3. Mean 
14C concentration versus time curves for maternal and fetal liver in pregnant rats 
after  receiving  an  i.v.  injection  of  7.5  mg/kg
  14C-psilocin.  Error  bars  represent  the  standard 
deviation of three rats. 
 
Figure 4. Mean 
14C concentration versus time curves for maternal and fetal lung in pregnant rats 
after  receiving  an  i.v.  injection  of  7.5  mg/kg
  14C-psilocin.  Error  bars  represent  the  standard 
deviation of three rats. Functional Foods in Health and Disease 2014; 4(6):232-244                                                           Page 238 of 244 
 
Figure 5. Mean 
14C concentration versus time curves for maternal and fetal heart in pregnant rats 
after  receiving  an  i.v.  injection  of  7.5  mg/kg
  14C-psilocin.  Error  bars  represent  the  standard 
deviation of three rats. 
 
Figure 6. Mean 
14C concentration versus time curves for maternal and fetal kidney in pregnant 
rats after receiving an i.v. injection of 7.5 mg/kg
 14C-psilocin. Error bars represent the standard 
deviation of three rats. 
The time course of psilocin-derived radioactivity in maternal spleen and muscle are depicted 
in Figure 7. The time course of psilocin-derived radioactivity in maternal brain and placenta are 
shown in Figure 8.  Functional Foods in Health and Disease 2014; 4(6):232-244                                                           Page 239 of 244 
 
Figure 7. Mean 
14C concentration versus time curves in maternal spleen and muscle of pregnant 
rats after receiving an i.v. injection of 7.5 mg/kg
 14C-psilocin. Error bars represent the standard 
deviation of three rats.  
 
Figure 8. Mean 
14C concentration versus time curves in maternal brain and placenta of pregnant 
rats after receiving an i.v. injection of 7.5 mg/kg
 14C-psilocin.  Error bars represent the standard 
deviation of three rats.  
Mean 
14C concentrations in the spleen, muscle and brain were the highest at 0.5 hr post-
dosing (the first time point of sampling) (Figures 7 and 8). However, 
14C levels in the placenta 
increased slowly to a maximum at about 4 hr post-dosing before decreasing with time (Figure 8).  
Mean 
14C AUC0-last in maternal and fetal tissues is summarized in Figure 9. All maternal 
tissues had much higher mean AUC0-last than the fetal tissues. Based on the results of these 
studies, the maternal tissues could be divided into the large AUC0-last organ group with ≥13 µg 
psilocin equivalents·hr/ml: blood, liver, lung, kidney, spleen, heart and placenta and the small Functional Foods in Health and Disease 2014; 4(6):232-244                                                           Page 240 of 244 
AUC0-last organ group with <13 µg psilocin equivalents·hr/ml: muscle, brain, and fetal tissues 
(Figure 9). 
   
Figure 9. Mean area under the concentration-time curves of various maternal and fetal tissues. 
Values represent the means + SD of three different rats; error bars up represent positive standard 
deviations. 
The t1/2β of 
14C-psilocin in maternal and fetal tissues is summarized in Figure 10.  The t1/2β of 
maternal lung, liver, kidney, brain and placenta were relatively short (<13 hr); they might be 
classified as fast eliminating organs. In contrast, the t1/2β of maternal heart, muscle, spleen, blood 
and  fetal  tissues  were  relatively  long (>13 hr); they might be classified as  slow  eliminating 
organs.  
 
Figure 10. Half-lives of 
14C elimination from maternal and fetal tissues. Values are the means + 
SD from of three different rats; error bars up represent the positive standard deviation.  
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Cumulative 
14C excretion in rat urine at 4 hr and 8 hr post-dosing were 33.2% and 35.9% of 
the administered dose, respectively.  These findings showed that the majority of the psilocin-
derived radioactivity was excreted in the urine during the first 4 hr of post-dosing period. 
An unknown metabolite of psilocin was detected in the chloroform-methanol extract of the 
urine; it had a Rf of 0.6 on the TLC plate developed in CHCl3:CH3OH (9:1 v/v). The unknown 
metabolite was not found in the urine of untreated rats. The mass spectral data of the unknown 
metabolite showed the following prominent fragmentation ions (relative intensities %): 207(100), 
189(75),  177(28),  167(75),  130(57),  105(70),  91(75).    The  fragmentation  pattern  and  the 
molecular ion (M)
+ at m/z 207 were consistent with the molecular formula of C10H9O4N which 
indicated a dihydroxyindoleacetic acid or its keto form.  
 
DISCUSSION:  
To  our  knowledge,  this  is  the  first  study  in  which  the  dispositional  kinetics  of  psilocin  is 
investigated  in  pregnant  rats  following  i.v.  administration.  Our  results  show  psilocin  readily 
crosses the blood-brain and placental barriers of pregnant rats, a finding which is consistent with 
psilocin being a small molecule with an octanol-water partition coefficient of 1.45 [21]. After 
crossing the placental barrier, psilocin distributes rapidly to the various fetal tissues. Psilocin 
likely crosses the blood-brain and placental barriers by passive diffusion since a concentration 
gradient is maintained between the maternal and fetal tissues throughout the study (Figures 2-6).  
In  the  present  study,  tissue 
14C  concentration  and  mean  AUC0-last  have  been  used  as 
quantitative measures of tissue exposure to psilocin [19].  Our results show that the AUC0-last of 
maternal tissues is much higher than the fetal tissues (Figure 9). These are consistent with the 
14C 
concentration   data in maternal and fetal tissues (Figures 2-6). In the present study, the kidney 
AUC0-last is the highest. This is followed by the AUC0-last of liver, brain, and blood in descending 
order. It should be noted that although the brain AUC0-last is low, it is related directly to the 
psychedelic and/or toxic effects of psilocin in animals (Figure 10). 
Kalberer et  al. [6] have reported that tissue 
14C concentration decreases in  the order of 
kidney > liver > brain > blood after administering 
14C-psilocin to male rats i.v. Our results are in 
agreement with their findings. In contrast, tissue 
14C concentration decreases in the order of liver 
> kidney > adrenal > brain after administering 
14C-psilocin to male rats p.o. [6].  Clearly, the 
route  of  administration  plays  an  important  role  in  tissue 
14C  concentration  as 
14C-psilocin 
administered by the oral route is metabolized by the gastrointestinal tract and liver before being 
distributed  to  other  organs  whereas 
14C-psilocin  administered  by  the  intravenous  route  is 
distributed to other organs first before reaching the liver. As a result, hepatic 
14C concentration is 
the highest after p.o. administration of 
14C-psilocin [6] and renal 
14C concentration is the highest 
after i.v. administration (Figure 9).  
Using 
14C-psilocin  in  the  present  study  complicates  our  efforts  to  obtain  a  precise 
pharmacokinetic analysis of psilocin in the pregnant rats because unchanged psilocin cannot be 
easily separated from its metabolites and quantified. However, the t1/2β of 
14C concentration in the 
maternal tissues most likely is defined by the time course of psilocin glucuronide concentration 
[22]. Thus, the highly perfused and active metabolic organs (i.e., maternal liver, lung, brain, 
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metabolic organs (i.e., maternal blood, heart, spleen, muscle and all fetal tissues) have relatively 
long t1/2β (>13 hr) (Figure 10). A comparison of the concentration-time profiles also shows that 
maternal tissue 
14C declines at faster rates than fetal tissue 
14C (Figures 3-6). An explanation for 
the slow decline of 
14C in the fetal tissues is not readily available but may be related to the 
underdeveloped  mixed-function  oxidase  and  monoamine  oxidase  enzymes  in  the fetuses.  As 
such, the t1/2β of 
14C concentration in the fetal tissues most likely is defined by the time course of 
unchanged psilocin concentration rather than psilocin glucuronide concentration. 
The mass spectral data show that the unknown metabolite in rat urine has a molecular ion 
(M)
+  at  m/z  207.  The  fragmentation  ions  at  m/z  189  (C10H7NO3),  177  (C9H7NO3),  167 
(C7H5NO4), 130 (C8H4NO), 105 (C6H3NO) and 91 (C6H3O) probably are resulted from (M-OH, 
H)
+, (M-COH, H)
+, (M-C3H3, H)
+, (M-OH, CH2COOH, H)
+, (M-CHCOH, CH2COOH, H)
+, and 
(M-CCH2COOH, NHCOH, H)
+, respectively. The m/z 177, 167, and 105 fragments are formed 
by cleaving the aromatic ring from the psilocin molecule, and the m/z 91 fragment probably is 
formed  by  eliminating  the  pyrrole  ring.  These  results  are  consistent  with  the  structure  of  a 
dihydroxyindoleacetic acid and/or its keto isomer both of which are the oxidation product of 4-
HIAA. We are unable to detect any 4-HIAA in the urine of rats after administering psilocin i.v. 
However, Kalberer et al. [6] have reported the presence of 4-HIAA in the urine of rats after p.o. 
administration.  Hasler  et  al.  [23]  also  have  been  unable  to  detect  4-HIAA in  the plasma of 
humans after intravenous administration of psilocin but are able to detect it in the plasma after 
oral administration. Our results are consistent with the findings in their studies.  
 
CONCLUSION: 
Psilocin and/or its metabolite(s) are able to cross the placental barrier of pregnant rats by passive 
diffusion. In view of the potential use of psilocybin as an anti-depressant, it is important to study 
the pharmacokinetics and tissue distribution of psilocin in pregnant rats. Because psilocin is 
eliminated slowly from the fetal tissues, consumption of magic mushrooms by humans should be 
avoided during pregnancy.  
 
List of abbreviations:  
GC-MS, gas chromatography-mass spectrometry; TLC, thin layer chromatography; Rf, retention 
factor; t1/2β, elimination half-life; AUC0-last, area under the concentration-time curve from 0 to last 
time  point;  4-HIAA,  4-hydroxy-3-indoleacetic  acid;  5-HT  receptors,  5-hydroxytryptamine 
receptors; i.v., intravenously; i.p., intraperitoneally; ln, natural logarithm. 
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